Advertisement

Topics

Alcon achieves US approval for CyPass® Micro-Stent, a micro invasive surgical device to treat glaucoma

03:15 EDT 2 Aug 2016 | GlobalNewsWire (2014)

This article has expired, however you can still download the PDF.
Preview:
Novartis International AG / Alcon achieves US approval for CyPass® Micro-Stent, a micro invasive surgical device to treat glaucoma . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this an...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "Alcon achieves US approval for CyPass® Micro-Stent, a micro invasive surgical device to treat glaucoma"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Acute Coronary Syndromes ACS
Acute Coronary Syndromes (ACS) is an umbrella term for situations where the blood supplied to the heart muscle is suddenly blocked. Treatment for acute coronary syndrome includes medicines and a procedure known as angioplasty, during which doctors inflat...